Dr. Marc E. Delclos, MD

Dr. Delclos practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Delclos' NPI, 1750497665, was assigned on August 22, 2006. Dr. Delclos graduated from Baylor College Of Medicine in 1992. Dr. Delclos' Texas license number on file is J4079.

Dr. Delclos' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Delclos' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service. Dmand AI also links Dr. Delclos to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Delclos practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Delclos' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Delclos is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Delclos' licenses on file in 3 states: Texas, Florida and Oklahoma.

Dmand AI lists bone cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation, pancreatic cancer radiation and prostate cancer radiation among the conditions Dr. Delclos treats.

CMS data shows 3,120 Medicare services from Dr. Delclos across 17 procedure codes in 2024, for 210 Medicare patients. Medicare paid $186,643 for them. Every service was in an office.

CMS counts 210 Medicare patients who saw Dr. Delclos in 2024. The largest group is 65 to 74, with 103 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Delclos' median patient age at 74, with 23% women.

In 2024, Dr. Delclos wrote 12 Medicare Part D claims. They cover 1 drug, with $170 in total drug cost. In 2018, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Delclos for performance year 2024, reported as part of a group. Dr. Delclos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Delclos as offering telehealth.

Dmand AI links 67 papers to Dr. Delclos, published from 2006 to 2021. 2011 was the busiest year, with 8. The most frequent topics are Radiotherapy Dosage, Fluorouracil and Antineoplastic Combined Chemotherapy Protocols. Dr. Delclos has published most often in Int J Radiat Oncol Biol Phys. Dr. Delclos' most frequent co-authors are Prajnan Das, MD, MPH, Sunil Krishnan, MD and Miguel A. Rodriguez-Bigas, MD.

CMS Open Payments shows 4 general payments to Dr. Delclos from 4 drug and device companies from 2017 to 2023. Food and beverage make up the largest share, 100% of the total. Astellas Pharma US Inc paid the most, $125.

Dr. Delclos graduated from Baylor College Of Medicine in 1992.

Dr. Delclos is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.